预约演示
更新于：2026-07-19
Dexamethasone
地塞米松
更新于：2026-07-19
概要
基本信息
简介地塞米松是一种具有糖皮质激素受体 (GR) 激动作用的小分子药物。 GR 广泛分布于各种细胞类型，负责无数生理反应，包括免疫和炎症反应。 地塞米松与 GR 结合，通过基因表达和蛋白质合成发挥激动作用，从而降低机体炎症反应，降低免疫系统活动。地塞米松已证明可以治疗多种疾病，包括但不限于光化性唇炎、轻链 (AL) 淀粉样变性、眼部炎症、黄斑水肿和过敏反应。 早在 1958 年 10 月 30 日，FDA 就批准了地塞米松。此外，英国国家卫生服务局和美国国立卫生研究院推荐地塞米松用于需要机械通气或补充氧气（无通气）的COVID-19患者。 |
药物类型 小分子化药 |
别名 CMIO-DEX、Decadron Phosphate、Dexamethasone Intravitreal Implant + [49] |
靶点 |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C22H29FO5 |
InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N |
CAS号50-02-2 |
关联
2,149
项与 地塞米松 相关的临床试验NCT07600151
A Clinical Phase I/II, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients
NCT07609706
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
NCT07072585
A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)
100 项与 地塞米松 相关的临床结果
登录后查看更多信息
100 项与 地塞米松 相关的转化医学
登录后查看更多信息
100 项与 地塞米松 相关的专利（医药）
登录后查看更多信息
70,485
项与 地塞米松 相关的文献（医药）2026-12-31Adipocyte
Wt1 facilitates visceral beige fat formation to combat abdominal obesity
Article
作者: He, Lin-Fei ; Chen, Jun-Ling ; Yang, Zhi-Chun ; Liao, Zhi-Mei
Visceral fat has weaker beige adipogenesis than subcutaneous fat with unclear mechanisms. The Wilms tumour gene (Wt1), a visceral adipocyte marker, is highly expressed in visceral adipose tissue (VAT) and visceral adipose-derived stem cells (vADSCs). In our present study, we found its protein levels in VAT decreased under high-fat diet or dexamethasone treatment, but rised in cold exposure or β3-adrenergic receptor agonist treatment, and positively correlate with uncoupling protein-1 (UCP1). Wt1 knockdown in vADSCs elevated PR domain containing 16 (PRDM16) and UCP1 mRNA but reduced their protein levels, alongside decreased ubiquitin-conjugating enzyme 9 (UBC9). Knockdown of UBC9 did not affect the mRNA levels of Wt1, PRDM16 or UCP1, but significantly reduced PRDM16 and UCP1 protein levels. Glucocorticoids including hydrocortisone, methylprednisolone and dexamethasone (Dex) dose-dependently suppress Wt1, UCP1, Alpha-enolase (ENO1) and Pyruvate kinase muscle isozyme M2 (PKM2) levels, which could be reversed by Wt1 overexpression. These findings explore the effects of Wt1 on beige remodelling of visceral adipose which might be related to the up-regulation of UBC9, and provide clues for treating abdominal obesity caused either by HFD or by glucocorticoids in a non-sympathetic-dependent manner.
2026-12-31PLATELETS
Abnormal expansion of peripheral helper T cells in primary immune thrombocytopenia
Article
作者: Yan, Zhenyu ; Zhao, Yajing ; Yu, Tianshu ; Jiang, Le ; Zhou, Yimin ; Liu, Jiaqi ; Zhu, Jiayi ; Liu, Xinguang ; Hou, Xiran ; Liu, Qian
Peripheral helper T (Tph) cells, a distinct T-cell subset defined as CD4+PD-1hiCXCR5- phenotypically, are increasingly recognized as key drivers of antibody-mediated autoimmunity; however, their role in primary immune thrombocytopenia (ITP) remains poorly defined. In this study, we evaluated circulating Tph cells in newly diagnosed ITP and characterized their dynamic changes following dexamethasone therapy. Circulating Tph cells were significantly expanded in patients with ITP and were positively correlated with bleeding severity, suggesting involvement of Tph cells in ITP pathophysiology. High-dose dexamethasone markedly reduced circulating Tph frequencies both in vitro and in vivo. Notably, persistently elevated Tph levels were observed in patients who were non-responsive to dexamethasone. Furthermore, plasma interleukin-21 levels declined in parallel with Tph reduction following dexamethasone treatment, and were positively correlated with Tph frequencies in untreated, newly diagnosed ITP patients, consistent with Tph-associated B-cell helper activity. Collectively, these findings identify Tph cells as a potential indicator of extrafollicular B-cell activation in ITP and highlight their relevance to dexamethasone therapeutic responsiveness.
2026-12-31DRUG DELIVERY
Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.
Review
作者: Huitema, Alwin D R ; O'neill, Allison F ; Bleyer, Archie ; Streefkerk, Nienke ; Bouffet, Eric ; Masroor, Amirhossein ; Sullivan, Michael ; Fresneau, Brice ; Maibach, Rudolf ; Van Grotel, Martine ; Hoetink, Alexander E ; Rajput, Kaukab M ; Papadakis, Vassilios ; Knight, Kristin ; Brock, Penelope R ; Geller, James I ; Kogner, Per ; Ansari, Marc ; Veal, Gareth J ; Van Den Heuvel-Eibrink, Marry M
Cisplatin-induced hearing loss (CIHL) in pediatric cancer patients is an irreversible and highly prevalent adverse effect with a devastating impact on quality of life. Sodium thiosulfate (STS) has recently been approved for systemic administration as an otoprotective agent in children. However, implementation of systemic STS has its challenges, and there is currently limited evidence to support local STS for children. This review investigates the potential value of locally administered otoprotective agents other than STS with a focus on future pediatric implementation. We conducted a systematic review on the efficacy and safety of locally applied non-STS otoprotective agents in in vivo settings. This included a summary of investigated drug delivery methods and administration routes. We identified 70 preclinical and eight clinical studies. Agents were categorized based on their biological mechanisms: anti-inflammatory, chemical deactivators, calcium blockers, biologicals, and miscellaneous mechanisms. Preclinical studies investigated 45 different agents. Dexamethasone and N-acetylcysteine were identified as efficacious agents recurrently and progressed to clinical trials. Dexamethasone was investigated in three randomized clinical trials (RCTs) and three non-randomized clinical studies and showed statistically significant but not clinically relevant benefit in two trials. N-acetylcysteine was investigated in two clinical trials and one RCT and was minimally effective in the RCT and in one clinical study. Our review did not identify available studies of local alternative otoprotective agents that could reliably replace systemic STS in terms of safety and efficacy for pediatric patients. Further research on the optimal dosage, delivery method, and timing of otoprotective agents is needed.
100 项与 地塞米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 黄斑水肿 | 美国 | 2026-03-11 | |
| 非感染性后葡萄膜炎 | 美国 | 2026-03-11 | |
| 免疫球蛋白轻链淀粉样变性 | 日本 | 2021-08-25 | |
| 免疫球蛋白轻链淀粉样变性 | 日本 | 2021-08-25 | |
| 眼部炎症 | 美国 | 2018-11-30 | |
| 眼科外科手术 | 美国 | 2018-11-30 | |
| 术后炎症 | 美国 | 2018-02-09 | |
| 糖尿病性黄斑水肿 | 欧盟 | 2010-07-26 | |
| 糖尿病性黄斑水肿 | 冰岛 | 2010-07-26 | |
| 糖尿病性黄斑水肿 | 列支敦士登 | 2010-07-26 | |
| 糖尿病性黄斑水肿 | 挪威 | 2010-07-26 | |
| 视网膜静脉阻塞相关黄斑水肿 | 欧盟 | 2010-07-26 | |
| 视网膜静脉阻塞相关黄斑水肿 | 冰岛 | 2010-07-26 | |
| 视网膜静脉阻塞相关黄斑水肿 | 列支敦士登 | 2010-07-26 | |
| 视网膜静脉阻塞相关黄斑水肿 | 挪威 | 2010-07-26 | |
| 后葡萄膜炎 | 欧盟 | 2010-07-26 | |
| 后葡萄膜炎 | 冰岛 | 2010-07-26 | |
| 后葡萄膜炎 | 列支敦士登 | 2010-07-26 | |
| 后葡萄膜炎 | 挪威 | 2010-07-26 | |
| 多发性骨髓瘤 | 日本 | 2010-06-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 新加坡 | 2024-02-19 | |
| 眼内炎 | 临床3期 | 美国 | 2023-12-18 | |
| 疼痛 | 临床3期 | 中国 | 2023-08-17 | |
| 疼痛 | 临床3期 | 中国 | 2023-08-17 | |
| 葡萄膜炎 | 临床3期 | 中国 | 2022-08-22 | |
| 视网膜炎 | 临床3期 | 美国 | 2021-10-12 | |
| 青光眼 | 临床3期 | - | 2020-11-01 | |
| 开角型青光眼 | 临床3期 | - | 2020-11-01 | |
| 浆细胞瘤 | 临床3期 | 美国 | 2016-11-29 | |
| 梅尼埃病 | 临床3期 | 美国 | 2015-10-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 11 | (Ixazomib + Lenalidomide + Dexamethasone + Zoledronic Acid) | 糧鑰憲憲齋壓淵壓鹹鑰 = 憲憲構艱鹽夢構餘遞鏇 夢夢製夢膚蓋淵夢網齋 (糧鑰鏇築憲繭衊願鹹廠, 糧鹽顧餘遞觸蓋範選築 ~ 膚鹽願鏇觸簾蓋鹹鏇衊) 更多 | - | 2026-06-30 | ||
(Zoledronic Acid) | 糧鑰憲憲齋壓淵壓鹹鑰 = 餘築網鏇艱壓顧齋鹹醖 夢夢製夢膚蓋淵夢網齋 (糧鑰鏇築憲繭衊願鹹廠, 遞鑰鹽壓襯鹹選壓積遞 ~ 憲窪襯膚範觸鑰廠蓋廠) 更多 | ||||||
临床1/2期 | 14 | 淵觸糧淵製築窪襯憲淵 = 顧積願遞壓餘齋選窪範 餘願範蓋憲襯範憲壓壓 (膚構範築艱糧顧襯衊憲, 選壓艱齋獵齋獵淵膚範 ~ 鹹蓋蓋選艱鹽壓夢鹽簾) 更多 | - | 2026-06-25 | |||
临床1/2期 | 20 | (0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone) | 窪網鹽淵鬱顧簾範願簾 = 齋築醖夢襯衊淵製壓製 襯範鏇顧構廠襯選糧築 (獵簾壓選糧夢獵網願餘, 憲衊構廠艱製鑰夢築膚 ~ 鑰鬱憲繭淵鹽築廠觸構) 更多 | - | 2026-06-16 | ||
(1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone) | 窪網鹽淵鬱顧簾範願簾 = 膚顧膚膚醖鹽觸膚簾齋 襯範鏇顧構廠襯選糧築 (獵簾壓選糧夢獵網願餘, 廠艱鹹築壓餘網遞觸襯 ~ 醖淵鏇窪簾獵範餘蓋鏇) 更多 | ||||||
临床3期 | 479 | Mezigdomide 1.0 mg + Kd | 繭膚遞衊簾壓膚鏇築艱(醖醖構選願獵餘鏇餘鑰) = 憲糧網襯遞繭選淵襯選 繭簾壓鬱觸壓艱築齋製 (廠壓製壓鏇艱窪鹽膚製 ) 更多 | 积极 | 2026-06-02 | ||
Kd | 繭膚遞衊簾壓膚鏇築艱(醖醖構選願獵餘鏇餘鑰) = 壓選淵蓋遞壓製選窪顧 繭簾壓鬱觸壓艱築齋製 (廠壓製壓鏇艱窪鹽膚製 ) 更多 | ||||||
临床3期 | 479 | 餘簾網淵簾餘蓋膚選遞(製糧壓積齋廠顧膚蓋蓋) = 餘觸簾餘積鹹壓範襯衊 壓願繭鬱壓齋衊淵構築 (鹹構襯觸淵廠願鏇鏇鬱 ) 更多 | 积极 | 2026-05-29 | |||
餘簾網淵簾餘蓋膚選遞(製糧壓積齋廠顧膚蓋蓋) = 繭襯鹽膚醖衊獵襯窪餘 壓願繭鬱壓齋衊淵構築 (鹹構襯觸淵廠願鏇鏇鬱 ) 更多 | |||||||
临床2期 | 17 | 選窪糧醖淵艱襯鏇淵窪(簾顧鬱選鬱襯築願獵選) = Grade 3-4 hematologic adverse events (AEs) included neutropenia (53%), thrombocytopenia (29%), and anemia (12%). Common non-hematologic AEs (all; grade 3-4) included blurred vision (65%; 6%); fatigue (65%; 0%); hypertension (59%; 6%); diarrhea (53%; 0%); and AST/ALT increase (47%; 6%). Infections occurred in 35% with no grade ≥3 events. 製範積獵蓋襯鏇鏇鏇夢 (觸鹽衊築艱蓋簾膚齋繭 ) 更多 | 积极 | 2026-05-29 | |||
(CD38-antibody-naïve patients) | |||||||
临床2期 | 69 | (Cohort 1) | 構餘製壓願製製餘廠願 = 觸蓋憲夢遞夢餘襯遞築 製範願選製齋製艱獵構 (壓選構獵鏇壓網膚餘構, 壓簾糧醖壓鬱鬱遞壓願 ~ 範繭憲窪衊網鏇鏇網餘) 更多 | - | 2026-05-29 | ||
(Cohort 2) | 構餘製壓願製製餘廠願 = 簾膚窪窪夢願鬱鬱構鹽 製範願選製齋製艱獵構 (壓選構獵鏇壓網膚餘構, 繭淵蓋構簾顧鬱襯選鹹 ~ 窪襯壓夢鏇獵構憲醖願) 更多 | ||||||
临床2期 | 186 | (Cohort A) | 鑰窪齋衊鏇醖選願糧願 = 顧鹹壓獵鹽夢範製獵鑰 網衊憲積齋窪鏇糧繭觸 (鹹選壓獵淵艱衊願蓋繭, 鏇網願顧觸築獵願淵範 ~ 觸壓齋憲鏇淵衊選範壓) 更多 | - | 2026-05-22 | ||
(Cohort B) | 鑰窪齋衊鏇醖選願糧願 = 膚繭選艱鹹觸鹹糧艱憲 網衊憲積齋窪鏇糧繭觸 (鹹選壓獵淵艱衊願蓋繭, 構淵繭衊窪觸積願鬱餘 ~ 顧積鑰膚壓艱淵獵夢積) 更多 | ||||||
临床3期 | 302 | Belantamab mafodotin, pomalidomide, and dexamethasone (BPd) | 願廠糧繭鏇醖淵衊廠壓(鹹齋艱齋構顧顧夢鹽網) = 糧觸蓋憲簾簾鹽鏇襯廠 鹹範觸範獵鑰衊鏇憲範 (繭襯齋衊膚糧衊構淵構, NR ~ NR) 更多 | 积极 | 2026-05-21 | ||
願廠糧繭鏇醖淵衊廠壓(鹹齋艱齋構顧顧夢鹽網) = 選鬱餘艱壓憲積壓膚襯 鹹範觸範獵鑰衊鏇憲範 (繭襯齋衊膚糧衊構淵構, 42.7 ~ NR) 更多 | |||||||
临床2期 | 11 | 廠觸淵餘窪鑰選鹽膚簾 = 壓範選構夢獵繭蓋鏇遞 齋顧網構醖憲餘襯艱餘 (窪獵簾願構觸齋顧網觸, 憲淵蓋壓膚壓獵構夢鹽 ~ 衊艱簾齋鏇膚襯壓淵糧) 更多 | - | 2026-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用